Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase. All Viatris’ biosimilars brands, including Ogivri & Hertraz (bTrastuzumab), Abevmy (bBevacizumab), Fulphila (bPegfilgrastim), Hulio (bAdalimumab), Nepexto…
Biocon Biologics Limited, a subsidiary of Biocon Ltd. (BIOCON), announced that the Company has been again recognized as an Asia IP Elite for 2023 by IAM (Intellectual Asset Management), the world’s biggest IP publication. Biocon Biologics has been awarded this prestigious accolade reserved for a select group of Asia-based corporations and research institutions that are…
Biocon Biologics said it has elevated Shreehas Tambe as Managing Director and CEO of the company with immediate effect, according to PTI report. Tambe was Deputy CEO of Biocon Biologics, a subsidiary of Bengaluru-based Biocon. He takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the Biocon Biologics board, the company said…
Biocon Biologics Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd., announced that Shreehas Tambe has been promoted to the position of Deputy Chief Executive Officer of Biocon Biologics Limited, effective from March 1, 2021. A Biocon veteran, Shreehas joined Biocon in 1997 and has, since then, taken on positions…